Skip to main content

Table 6 Comparison of microbiological data susceptibility tests between our study and Camargo et al. study [1]

From: Evaluation of Candida bloodstream infection and antifungal utilization in a tertiary care hospital

Variables n(%)
2002 a 2007*
Candida albicans (n = 27)  
  Amphotericin B (n = 27)
  Susceptible 27 (100.0)
  Fluconazole (n = 27)
  Susceptible 27 (100.0)
Candida non-albicans (n = 51)  
  Amphotericin B (n = 51)
  Susceptible 51 (100.0)
  Fluconazole (n = 51)
  Susceptible 42 (82.3)
2012 a 2016**
Candida albicans (n = 42)  
  Amphotericin B (n = 40)
  Susceptible 40 (100.0)
  Fluconazole (n = 41)
  Susceptible 41 (100.0)
  Voriconazole (n = 41)
  Susceptible 41 (100.0)
  Caspofungin (n = 1)
  Susceptible 1 (100.0)
  Anidulafungin (n = 3)
  Susceptible 3 (100.0)
Candida non-albicans (n = 73)  
  Amphotericin B (n = 72)
  Susceptible 72 (100.0)
  Fluconazole (n = 64)
   Susceptible 55 (85.9)
   Resistant 3 (4.7)
   Intermediate 6 (9.4)
  Voriconazole (n = 64)
   Susceptible 63 (98.4)
   Intermediate 1 (1.6)
  Caspofungin (n = 10)
   Susceptible 9 (90.0)
   ntermediate 1 (10.0)
  Anidulafungin (n = 11)
   Susceptible 8 (72.7)
   Intermediate 3 (27.3)
  1. Category variables presented by absolute and relative frequencies
  2. *Data from Camargo TZS, et al. study [1]. **Data from our current study